Correction: The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer

• C. Hage,
• V. Rausch,
• N. Giese,
• T. Giese,
• F. Schönsiegel,
• S. Labsch,
• C. Nwaeburu,
• J. Mattern,
• J. Gladkich,
• I. Herr

Affiliations

C. Hage

Section Surgical Research, Molecular OncoSurgery, University Clinic of Heidelberg

V. Rausch

Section Surgical Research, Molecular OncoSurgery, University Clinic of Heidelberg

N. Giese

Department of General Surgery, Institute for Immunology, University of Heidelberg

T. Giese

Department of Molecular Immunodiagnostics, Institute for Immunology, University of Heidelberg

F. Schönsiegel

Section Surgical Research, Molecular OncoSurgery, University Clinic of Heidelberg

S. Labsch

Section Surgical Research, Molecular OncoSurgery, University Clinic of Heidelberg

C. Nwaeburu

Section Surgical Research, Molecular OncoSurgery, University Clinic of Heidelberg

J. Mattern

Section Surgical Research, Molecular OncoSurgery, University Clinic of Heidelberg

J. Gladkich

Section Surgical Research, Molecular OncoSurgery, University Clinic of Heidelberg

I. Herr

Section Surgical Research, Molecular OncoSurgery, University Clinic of Heidelberg